CN115867551A - 单一疗法和组合疗法 - Google Patents

单一疗法和组合疗法 Download PDF

Info

Publication number
CN115867551A
CN115867551A CN202180043458.3A CN202180043458A CN115867551A CN 115867551 A CN115867551 A CN 115867551A CN 202180043458 A CN202180043458 A CN 202180043458A CN 115867551 A CN115867551 A CN 115867551A
Authority
CN
China
Prior art keywords
unsubstituted
substituted
compound
group
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043458.3A
Other languages
English (en)
Chinese (zh)
Inventor
艾哈迈德·阿布迪·萨玛塔
李佳莉
黄琴华
凯文·杜安·邦克
费尔南多·多纳特
布伦特·克莱顿·博伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ricoram Ip Holding Co ltd
Original Assignee
Ricoram Ip Holding Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricoram Ip Holding Co ltd filed Critical Ricoram Ip Holding Co ltd
Publication of CN115867551A publication Critical patent/CN115867551A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180043458.3A 2020-05-15 2021-05-12 单一疗法和组合疗法 Pending CN115867551A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063025490P 2020-05-15 2020-05-15
US63/025,490 2020-05-15
US202063040832P 2020-06-18 2020-06-18
US63/040,832 2020-06-18
US202063089419P 2020-10-08 2020-10-08
US63/089,419 2020-10-08
US202163160325P 2021-03-12 2021-03-12
US63/160,325 2021-03-12
US202163161828P 2021-03-16 2021-03-16
US63/161,828 2021-03-16
PCT/US2021/032094 WO2021231653A1 (en) 2020-05-15 2021-05-12 Mono- and combination therapies

Publications (1)

Publication Number Publication Date
CN115867551A true CN115867551A (zh) 2023-03-28

Family

ID=78525230

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043458.3A Pending CN115867551A (zh) 2020-05-15 2021-05-12 单一疗法和组合疗法

Country Status (12)

Country Link
US (1) US20230210854A1 (cg-RX-API-DMAC7.html)
EP (1) EP4153594A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023526283A (cg-RX-API-DMAC7.html)
KR (1) KR20230010729A (cg-RX-API-DMAC7.html)
CN (1) CN115867551A (cg-RX-API-DMAC7.html)
AU (1) AU2021271844A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023254A2 (cg-RX-API-DMAC7.html)
CA (1) CA3182270A1 (cg-RX-API-DMAC7.html)
IL (1) IL298201A (cg-RX-API-DMAC7.html)
MX (1) MX2022014131A (cg-RX-API-DMAC7.html)
TW (1) TWI906299B (cg-RX-API-DMAC7.html)
WO (1) WO2021231653A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ
WO2023147297A2 (en) * 2022-01-25 2023-08-03 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2024102650A1 (en) * 2022-11-08 2024-05-16 Zeno Management, Inc. Intermittent dosing regimen for azenosertib in treating cancer
TW202502354A (zh) * 2023-06-02 2025-01-16 美商薩諾管理公司 同源重組修復缺陷(hrd)作為預測性生物標記以便使用wee1抑制劑治療癌症
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy
WO2025226653A1 (en) * 2024-04-23 2025-10-30 Zeno Management, Inc. Wee1 inhibitor combination therapy dosing regimen
WO2025245463A1 (en) * 2024-05-23 2025-11-27 Merck Patent Gmbh Combination therapies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CN111094253A (zh) * 2017-08-01 2020-05-01 里科瑞尔姆Ip控股有限责任公司 1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮类似物
CN112142748A (zh) * 2019-06-28 2020-12-29 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3043945A1 (en) * 2016-11-16 2018-05-24 Sui Xiong Cai 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6h)-ones

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094253A (zh) * 2017-08-01 2020-05-01 里科瑞尔姆Ip控股有限责任公司 1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮类似物
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CN112142748A (zh) * 2019-06-28 2020-12-29 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALICE LALLO ET AL.: "The Combination of the PARP Inhibitor Olapariband the WEE1 Inhibitor AZD1775 as a NewTherapeutic Option for Small Cell Lung Cancer", 《CLIN CANCER RES》, 25 June 2018 (2018-06-25), pages 5153 - 5164 *
LESLIE A.PARSELS ET AL.: "PARP1 Trapping and DNA Replication StressEnhance Radiosensitization with CombinedWEE1 and PARP Inhibitors", 《MOL CANCER RES》, 13 November 2017 (2017-11-13), pages 222 - 232 *
PRAVEEN VIKAS ET AL.: "Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors", 《FRONTIERS IN ONCOLOGY》, 28 April 2020 (2020-04-28), pages 1 - 10 *
YONG FANG ET AL.: "Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy", 《CANCER CELL》, 10 June 2019 (2019-06-10), pages 851 - 867 *
YOO-YOUNG LEE ET AL.: "Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer", 《SCIENTIFIC REPORTS》, 28 October 2019 (2019-10-28), pages 1 - 11 *

Also Published As

Publication number Publication date
KR20230010729A (ko) 2023-01-19
IL298201A (en) 2023-01-01
JP2026083268A (ja) 2026-05-19
WO2021231653A1 (en) 2021-11-18
US20230210854A1 (en) 2023-07-06
EP4153594A1 (en) 2023-03-29
EP4153594A4 (en) 2024-05-01
AU2021271844A1 (en) 2022-12-08
TWI906299B (zh) 2025-12-01
NZ793883A (en) 2025-11-28
JP2023526283A (ja) 2023-06-21
CA3182270A1 (en) 2021-11-18
TW202207939A (zh) 2022-03-01
BR112022023254A2 (pt) 2023-02-07
MX2022014131A (es) 2023-01-05

Similar Documents

Publication Publication Date Title
TWI906299B (zh) 單一療法及組合療法
CN115135325B (zh) 组合
CN115023224A (zh) 组合
JP7631348B2 (ja) 組み合わせ
RU2853597C1 (ru) Моно- и комбинированная терапия
CN115023229A (zh) 组合
CN116744919A (zh) Bcl-2抑制剂与化疗药的组合
CN115666574A (zh) 组合
WO2026043617A1 (en) Compounds and methods of use thereof for treatment of health conditions and drug screening

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination